Country websites
Australia (Ascent)
Australia (Spirit)
Austria
Belgium
Bosnia and Herzegovina
Bulgaria
Brazil
Canada (Cobalt)
Canada (Watson)
China
Czech Republic
Denmark
Finland
France (Arrow)
Germany
Germany (Arrow)
Greece (Alet)
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Ireland (Arrow)
Japan
Lithuania
Luxemburg
Malaysia (DHA)
Malta
Mongolia
New Zealand (Arrow)
Netherlands
Norway
Poland
Poland (Arrow)
Portugal
Romania
Russia
Serbia
Singapore (DHA)
Spain
Sweden
Sweden (Arrow)
Switzerland
Turkey
Ukraine
United Kingdom
United Kingdom (Arrow)
United Kingdom (Eden)
About Actavis
Company Profile
CEO Message
Mission / Culture
Executive Leadership
Global Locations
Facilities
Commercial
Americas
Europe
Asia Pacific
Global Business
Actavis Pharma
North America
Europe
Asia & MEA
Actavis Specialty Brands
United States
Canada & LATAM
Biosimilars
Distribution
Anda
PractRx
Intellogics
Products
R&D
R&D Sites
Generics R&D
Biosimilars R&D
Brands R&D
Therapeutic Classes
Generics
Biosimilars
Brands
Drug Safety
Quality
U.S. Product Database
Investors
Press Releases
Financial Information
SEC Filings
Annual Reports
Quarterly Results
2013 Proxy Materials
Corporate Fact Sheet
Corporate Governance
Executive Officers and Directors
Committee Composition
Committee Charters
Code of Conduct
Governance Guidelines
Insider Transactions
Actavis Compliance Program
Events and Presentations
Stock Information
Stock Quote
Stock Chart
Historical Price Lookup
Investment Calculator
Shareholder Services
FAQs
Information Requests
E-mail Alerts
Analyst Coverage
Responsibility
Environmental
Employees
Facilities & Manufacturing
Partners
Community
Media
Corporate Profile
Press releases
Resources
Careers
Working at Actavis
Culture
Benefits
Career Opportunities
University
On-Campus Recruiting
Internships & Programs
Recent Graduates
Applying to Actavis in the US
Contact Us
Watson and Actavis are now Actavis
learn more
Recent News
14/05/2013 Announcement Under Irish Takeover Rules Relevant Securities in Issue
13/05/2013 Actavis' NDA for Progestin-Only Patch Accepted for Filing by FDA
13/05/2013 Actavis Cancels Presentation at Bank of America Merrill Lynch Healthcare...
We are the New Actavis
We are the New Actavis
A Global Leader in Generics
A Global Leader in Generics
Aggressively Expanding Global Brands
Aggressively Expanding Global Brands
Building a Foundation in Biosimilars
Building a Foundation in Biosimilars
Enhancing Customer and Shareholder Value
Enhancing Customer and Shareholder Value
NYSE:ACT
NYSE:ACT
Act One
NYSE
ACT:
-
Product Database
Commitment to Quality